Background
Cristina Adriana Popa
To INFINITI and Beyond: SGLT2 Inhibitors in ...

This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients
Background
Cristina Adriana Popa
POTCAST- K+ Pop and Arrhythmia Drop

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

POTCAST- K+ Pop and Arrhythmia Drop
Background
Brian Rifkin
A VALIANT effort to combat complement disorders ...

This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.

A VALIANT effort to combat complement disorders with pegcetacoplan
news
Cristina Adriana Popa
Top Stories in Nephrology 2025

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

Top Stories in Nephrology 2025
Background
Brian Rifkin
Dialyze Less, Recover More? AKI’s Chance to Get ...

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D

canvas

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.